More Access and Evidence Articles

Access and Evidence

Bringing innovation to rare disease patients in Europe

Izzy Gladstone, (Feb 17, 2021)

Johanna Friedl-Naderer, President, Europe, Canada & Partner Markets, Biogen on how collaboration between governments and industry can lead to better patient outcomes.
Access and Evidence

#Icare4Rare campaign launches to raise awareness ahead of Rare Disease Week 2021

Izzy Gladstone, (Feb 11, 2021)

To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021
Access and Evidence

Survey results: Accelerating digital transformation during COVID-19

Nicola Davies, (Sep 4, 2020)

View the results of a survey of over 1000 pharma executives on the impact COVID-19 has had and will have on their operations
Access and Evidence

A burning desire to make a difference for patients

Andrew Stone, (Apr 19, 2020)

Annexus Health, eyeforpharma’s 2020 Health Start-up winner is on a mission for patients
Access and Evidence

From reactive to predictive: Concerto’s new compositions

Andrew Stone, (Apr 10, 2020)

Artificial Intelligence has only just begun to unlock high value innovation. The latest predictive tools will break new ground, says Concerto HealthAI’s Jeff Elton
Access and Evidence

Evolving HTA frameworks to accelerate innovation

Andrew Stone, (Mar 14, 2020)

Iterative evidence generation and demonstrating value over time could help unlock delays in getting cures out, saving more lives, says Janssen’s Clare Hague
Access and Evidence

Can we afford to pay for future cures?

Ulrich Neumann, (Jan 24, 2020)

Medical innovation is racing ahead of healthcare’s ability to innovate on payments, but new ideas are emerging
Access and Evidence

Into pharma's roaring twenties

Paul Simms, (Jan 14, 2020)

A new decade is here. And despite the incredible science, pharma is ill-equipped.
Access and Evidence

Advancing RWE together with academia

Katie Osborne, (Jan 2, 2020)

Pharma can realise the potential of RWE faster by collaborating more effectively with academia but first it must build trust
Access and Evidence

Prescription drug pricing: The times they are a changin’

Ulrich Neumann, (Nov 25, 2019)

The political mood in the US on drug pricing at a national and state level is putting the pressure on pharma to demonstrate value

Pages